Outside of the USA, click here for more information.
Press Esc to close

A unique solution for the dietary management of glycogen storage disease (GSD)

About Glycosade

What is glycosade?

Vitaflo® has worked with leading metabolic centers, scientists and individuals with GSD in the development of Glycosade®, a hydrothermally processed high amylopectin cornstarch that can help keep blood sugar levels within the normal reference range for longer compared to uncooked cornstarch.

How do you take your glycogen storage disease?

Glycosade must only be started after consulting with your healthcare professional.

  • Glycosade can be mixed and taken in the same way as uncooked cornstarch (UCCS).
  • Always consult with your doctor or dietitian before making any changes to your diet.

Age Indication

  • Glycosade is suitable for use from 5 years of age in the United States.

Why use Glycosade®?

  • Clinical evaluation comparing Glycosade® to uncooked cornstarch for overnight dietary management of GSD has shown that Glycosade®:
    • Significantly prolongs the duration of normoglycemia1-5
    • Supports safe overnight fasting1-5
    • Supports adherence and quality of sleep due to avoidance of a middle-of-the-night dose5-7
    • Supports metabolic control4,5

Talk to your Healthcare Professional

Glycosade must only be started after consulting with your healthcare provider. Speak to your healthcare provider to learn more about Glycosade and find out if it may be appropriate for you.

Nutrition Information

Unflavored – Ingredient: Corn starch.

View full datasheet.

For dosage and administration, please consult your healthcare professional.


[1] Correia CE, Bhattacharaya K, Lee PJ, Shuster JJ, Thriaque DW, Shankar MN, Smit PA, Weinstein DA. Use of modifi ed cornstarch therapy to extend fasting in glycogen storage disease types Ia and Ib. American Journal of Clinical Nutrition (2008) 88: 1272-6.
[2] Bhattacharya K, Orton RC, Qi X, Mundy H, Morley DW, Champion MP, Eaton S, Tester RF, Lee PJ. A novel starch for the treatment of glycogen storage diseases. Journal of Inherited Metabolic Disease (2007) 30: 350-7.
[3] Maritz CM, Cousins A, Murphy E. Reduction in insulin response in a patient with GSD1 using a new modified starch: Case report. Molecular Genetics and Metabolism (2009) 98: 39.
[4] Humphrey MS. The use of Glycosade™ to extend fasting tolerance and improve oral intake in GSD1b. Molecular Genetics and Metabolism (2009) 98:116.
[5] Mullally M, Mundy H, Champion M, Gick J, Eardley J, Emery P. Retrospective Evaluation of Clinical Practice: Using a Modified Cornstarch in the Management of Glycogen Storage Disease. Journal of Inherited Metabolic Disease (2010) 33(Suppl 1): S72.